Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Pizzuti

Showing results (91-100 of 115) with videos related to

Pageof 12
Sort By:
Experimental and Molecular Pathology|May 11, 2026
A WNT/β-catenin-associated transcriptional program predicts survival outcomes in patients with hepatocellular carcinomaStefano Scalera, Laura Cipriani, Andrea Scarinci, et al.
Frontiers in Oncology|July 13, 2023
Pathologic response and survival after neoadjuvant chemotherapy with or without pertuzumab in patients with HER2-positive breast cancer: the Neopearl nationwide collaborative studyAgnese Fabbri, Fabrizio Nelli, Andrea Botticelli, et al.
Scientific Reports|September 8, 2017
Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt studyLaura Pizzuti, Paolo Marchetti, Clara Natoli, et al.
Journal of Translational Medicine|February 7, 2018
Expression of the Hippo transducer TAZ in association with WNT pathway mutations impacts survival outcomes in advanced gastric cancer patients treated with first-line chemotherapyElisa Melucci, Beatrice Casini, Livia Ronchetti, et al.
Journal of Cellular Physiology|July 16, 2017
Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life settingTeresa Gamucci, Laura Pizzuti, Isabella Sperduti, et al.
Cancers|August 10, 2024
DNA Damage Response in Early Breast Cancer: A Phase III Cohort in the Phobos StudyEriseld Krasniqi, Cristiana Ercolani, Anna Di Benedetto, et al.
Journal for Immunotherapy of Cancer|August 8, 2020
Efficacy of immunotherapy in lung cancer with co-occurring mutations in NOTCH and homologous repair genesMarco Mazzotta, Marco Filetti, Mario Occhipinti, et al.
Journal of Cellular Physiology|November 19, 2016
A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast CancerTeresa Gamucci, Lucia Mentuccia, Clara Natoli, et al.
Cancers|October 14, 2022
The Impact of the Hippo Pathway and Cell Metabolism on Pathological Complete Response in Locally Advanced Her2+ Breast Cancer: The TRISKELE Multicenter Prospective StudyEriseld Krasniqi, Francesca Sofia Di Lisa, Anna Di Benedetto, et al.
Cancer Biology & Therapy|January 17, 2018
Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumabLaura Pizzuti, Domenico Sergi, Isabella Sperduti, et al.
Pageof 12

Showing results (91-100 of 115) with videos related to

Sort By:
Pageof 12
Experimental and Molecular Pathology|May 11, 2026
A WNT/β-catenin-associated transcriptional program predicts survival outcomes in patients with hepatocellular carcinomaStefano Scalera, Laura Cipriani, Andrea Scarinci, et al.
Frontiers in Oncology|July 13, 2023
Pathologic response and survival after neoadjuvant chemotherapy with or without pertuzumab in patients with HER2-positive breast cancer: the Neopearl nationwide collaborative studyAgnese Fabbri, Fabrizio Nelli, Andrea Botticelli, et al.
Scientific Reports|September 8, 2017
Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt studyLaura Pizzuti, Paolo Marchetti, Clara Natoli, et al.
Journal of Translational Medicine|February 7, 2018
Expression of the Hippo transducer TAZ in association with WNT pathway mutations impacts survival outcomes in advanced gastric cancer patients treated with first-line chemotherapyElisa Melucci, Beatrice Casini, Livia Ronchetti, et al.
Journal of Cellular Physiology|July 16, 2017
Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life settingTeresa Gamucci, Laura Pizzuti, Isabella Sperduti, et al.
Cancers|August 10, 2024
DNA Damage Response in Early Breast Cancer: A Phase III Cohort in the Phobos StudyEriseld Krasniqi, Cristiana Ercolani, Anna Di Benedetto, et al.
Journal for Immunotherapy of Cancer|August 8, 2020
Efficacy of immunotherapy in lung cancer with co-occurring mutations in NOTCH and homologous repair genesMarco Mazzotta, Marco Filetti, Mario Occhipinti, et al.
Journal of Cellular Physiology|November 19, 2016
A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast CancerTeresa Gamucci, Lucia Mentuccia, Clara Natoli, et al.
Cancers|October 14, 2022
The Impact of the Hippo Pathway and Cell Metabolism on Pathological Complete Response in Locally Advanced Her2+ Breast Cancer: The TRISKELE Multicenter Prospective StudyEriseld Krasniqi, Francesca Sofia Di Lisa, Anna Di Benedetto, et al.
Cancer Biology & Therapy|January 17, 2018
Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumabLaura Pizzuti, Domenico Sergi, Isabella Sperduti, et al.
Pageof 12